Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Fusce ullamcorper dapibus
Original price was: $55.00.$41.00Current price is: $41.00.Add to cartVestibulum quis augue sem. Curabitur non vehicula elit, et cursus tortor. Quisque placerat velit nec nulla sodales, porttitor mattis tortor porta. Praesent gravida leo nibh, vel semper nulla lobortis vel. Donec nisl velit, iaculis ac dolor eget, blandit elementum urna. Mauris pellentesque posuere pellentesque. Nunc fermentum purus a consequat fringilla. Donec finibus suscipit erat in pharetra
-
Quick View
Mauris elit magna, aliquet
$50.00Add to cartFusce sagittis tellus eget ante gravida euismod. Mauris interdum, neque eu hendrerit aliquet, diam nisi fringilla nisi, at convallis ante velit sed erat. Vestibulum mollis lorem ut molestie pharetra. Sed pretium quam lacinia, placerat urna a, tincidunt massa. Mauris elit magna, aliquet blandit mauris eu
-
Quick View
Fusce congue cursus metus
$88.00Add to cartNulla feugiat felis tempor sem finibus egestas. Maecenas est nunc, faucibus in tristique nec, ornare et tortor. Mauris maximus lectus vel metus finibus, eget ullamcorper leo auctor. Donec at interdum nibh, in blandit massa. Nam pulvinar mollis quam
-
Quick View
Phasellus varius turpis
$56.00Add to cartPhasellus varius turpis consequat enim tincidunt, id aliquam orci hendrerit. Curabitur quis accumsan nisl, in condimentum magna. Fusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui.
Reviews
There are no reviews yet.